Radiotherapy and adjuvant trastuzumab in operable breast cancer: Tolerability and adverse event data from the NCCTG phase III trial N9831

Journal of Clinical Oncology

Volumn 27, Issue 16, 2009, Pages 2638-2644

  Halyard, Michele Y ^a   Pisansky, Thomas M ^a   Dueck, Amylou C ^a   Suman, Vera ^a   Pierce, Lori ^a   Solin, Larry ^a   Marks, Larry ^a   Davidson, Nancy ^a   Martino, Silvana ^a   Kaufman, Peter ^a   Kutteh, Leila ^a   Dakhil, Shaker R ^a   Perez, Edith A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG TOLERABILITY; DYSPNEA; FOLLOW UP; GRANULOCYTE; HUMAN; LEUKOCYTE; LUNG INFILTRATE; MASTECTOMY; NEUTROPHIL; PARTIAL MASTECTOMY; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DERMATITIS; RANDOMIZED CONTROLLED TRIAL; ADENOCARCINOMA; ADJUVANT THERAPY; ADULT; AGED; BREAST TUMOR; FEMALE; MIDDLE AGED; MULTICENTER STUDY; RISK; RISK ASSESSMENT; SEGMENTAL MASTECTOMY; TIME; TREATMENT OUTCOME; UNITED STATES;

ADENOCARCINOMA; ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; MASTECTOMY; MASTECTOMY, SEGMENTAL; MIDDLE AGED; ODDS RATIO; PACLITAXEL; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; TIME FACTORS; TREATMENT OUTCOME; UNITED STATES; YOUNG ADULT;

EID: 66849118557     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.9549     Document Type: Article

References (39)

1. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, et al: Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672, 2005
2. Slamon DJ, Leyland-Jones B, Shak S, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783-792, 2001
3. Ménard S, Balsari A, Casalini P, et al: HER-2-positive breast carcinomas as a particular subset with peculiar clinical behaviors. Clin Cancer Res 8:520-525, 2002
4. Perou CM, Sorlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000
5. Hayes DF, Thor AD: C-erbB-2 in breast cancer: Development of a clinically useful marker. Semin Oncol 29:231-245, 2002
6. Perez EA, Romond EH, Suman VJ, et al: Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer. J Clin Oncol 25:6s, 2007 (suppl; abstr 512)
7. Perez EA, Suman VJ, Davidson NE, et al: Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 26:1231-1238, 2008
8. Liang K, Lu Y, Jin W, et al: Sensitization of breast cancer cells to radiation by trastuzumab. Mol Cancer Ther 2:1113-1120, 2003
9. Cuzick J, Stewart H, Rutqvist L, et al: Causespecific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 12:447-453, 1994
10. Marks LB, Yu X, Prosnitz RG, et al: The incidence and functional consequences of RT-associated cardiac perfusion defects. Int J Radiat Oncol Biol Phys 63:214-223, 2005
11. Leyland-Jones B, Gelmon K, Ayoub JP, et al: Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 21:3965-3971, 2003
12. Prosnitz RG, Chen YH, Marks LB: Cardiac toxicity following thoracic radiation. Semin Oncol 32:S71-S80, 2005
13. Prosnitz RG, Marks LB: Radiation-induced heart disease: Vigilance is still required. J Clin Oncol 23:7391-7394, 2005
14. Perez EA, Rodeheffer R: Clinical cardiac tolerability of trastuzumab. J Clin Oncol 22:322-329, 2004
15. Tan-Chiu E, Yothers G, Romond E, et al: Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 23:7811-7819, 2005
16. Belkacémi Y, Gligorov J, Ozsahin M, et al: Concurrent trastuzumab with adjuvant radiotherapy in HER2-positive breast cancer patients: Acute toxicity analyses from the French multicentric study. Ann Oncol 19:1110-1116, 2008
17. Romond EH, Perez EA, Bryant J, et al: Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684, 2005
18. Recht A, Edge S, Solin L: Postmastectomy radiotherapy: Clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539-1569, 2001
19. Palmieri FM, Perez EA: Managing high-risk breast cancer. Semin Oncol Nurs 23:29-36, 2007
20. Arbuck S, McCLure J, Ivy S, et al: The Common Toxicity Criteria Manual. http://ctep.cancer .gov/protocolDevelopment/electronic-applications/ ctc.htm
21. Fine J, Gray R: A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509, 1999
22. Smith I, Procter M, Gelber RD, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369:29-36, 2007
23. Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al: Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 354:809-820, 2006
24. Slamon D, Eiermann W, Robert N, et al: Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: Second interim efficacy analysis. Presented at 29th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 14-17, 2006
25. Halyard MY, Grado GL, Schomberg PJ, et al: Conservative therapy of breast cancer. The Mayo Clinic experience. Am J Clin Oncol 19:445-450, 1996
26. Dörr W, Bertmann S, Herrmann T: Radiation induced lung reactions in breast cancer therapy. Modulating factors and consequential effects. Strahlenther Onkol 181:567-573, 2005
27. Lind PA, Marks LB, Hardenbergh PH, et al: Technical factors associated with radiation pneumonitis after local +/- regional radiation therapy for breast cancer. Int J Radiat Oncol Biol Phys 52:137-143, 2002
28. Radzikowska E, Szczepulska E, Chabowski M, et al: Organising pneumonia caused by trastuzumab (Herceptin) therapy for breast cancer. Eur Respir J 21:552-555, 2003
29. Vahid B, Mehrotra A: Trastuzumab (Herceptin)-associated lung injury. Respirology 11:655-658, 2006
30. Clamon G, Herndon J, Kern J, et al: Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810 - A phase II trial of Cancer and Leukemia Group B. Cancer 103: 1670-1675, 2005
31. Taghian AG, Assaad SI, Niemierko A, et al: Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel. J Natl Cancer Inst 93:1806-1811, 2001
32. Hanna YM, Baglan KL, Stromberg JS, et al: Acute and subacute toxicity associated with concurrent adjuvant radiation therapy and paclitaxel in primary breast cancer therapy. Breast J 8:149-153, 2002
33. Yu TK, Whitman GJ, Thames HD, et al: Clinically relevant pneumonitis after sequential paclitaxel-based chemotherapy and radiotherapy in breast cancer patients. J Natl Cancer Inst 96: 1676-1681, 2004
34. Rutqvist LE, Lax I, Fornander T, et al: Cardiovascular mortality in a randomized trial of adjuvant radiation therapy versus surgery alone in primary breast cancer. Int J Radiat Oncol Biol Phys 22:887-896, 1992
35. Giordano SH, Kuo YF, Freeman JL, et al: Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst 97:419-424, 2005
36. Patt DA, Goodwin JS, Kuo YF, et al: Cardiac morbidity of adjuvant radiotherapy for breast cancer. J Clin Oncol 23:7475-7482, 2005
37. Raj KA, Marks LB, Prosnitz RG: Late effects of breast radiotherapy in young women. Breast Dis 23:53-65, 2005
38. Stewart JR, Fajardo LF, Gillette SM, et al: Radiation injury to the heart. Int J Radiat Oncol Biol Phys 31:1205-1211, 1995
39. Hooning MJ, Aleman BM, van Rosmalen AJ, et al: Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 64:1081-1091, 2006